Search

Your search keyword '"D'Alise, Anna Morena"' showing total 158 results

Search Constraints

Start Over You searched for: Author "D'Alise, Anna Morena" Remove constraint Author: "D'Alise, Anna Morena"
158 results on '"D'Alise, Anna Morena"'

Search Results

2. Characterization of shared neoantigens in Endometrial Cancer with Microsatellite Instability

4. Supplementary Figure 6 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine

5. Data from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine

6. Supplementary Figure 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine

7. Supplementary Figure 5 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine

8. Supplementary Table 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine

9. Supplementary Figure 2 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine

10. Supplementary Figure 3 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine

11. Supplementary Figure 4 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine

12. Phase I trial of viral vector based personalized vaccination elicits robust neoantigen specific antitumor T cell responses

13. Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine

14. Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine

17. Adenovirus Encoded Adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve Adenovirus based vaccines against infectious diseases and cancer

18. Abstract LB196: NOUS-PEV, a personalized cancer immunotherapy targeting neoantigens, induces long lasting, tumor infiltrating memory T cells

19. Table S1 from A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability

20. Data from A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability

22. Supplementary Data from A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability

24. Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade

25. Adenoviral-based vaccine promotes neoantigen-specific CD8 + T cell stemness and tumor rejection

26. Interindividual variation in human T regulatory cells

27. Abstract LB008: Characterization of immune correlates of clinical activity for Nous-209, an off-the-shelf immunotherapy, with pembrolizumab for treatment of tumors characterized by microsatellite instability (MSI)

28. First clinical and immunogenicity results including all subjects enrolled in a phase I study of Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability (dMMR/MSI).

35. Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion

36. 410 Phase I interim study results of Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability (dMMR/MSI)

37. VENUS, a Novel Selection Approach to Improve the Accuracy of Neoantigens’ Prediction

38. Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness and tumor rejection.

39. A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability.

40. MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans

41. Generation of a Novel Mesothelin-Targeted Oncolytic Herpes Virus and Implemented Strategies for Manufacturing

42. Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment

43. Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of Herpes Simplex Oncolytic Virus

45. A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability

48. Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries

49. Abstract B105: A cancer vaccine targeting many neoantigens is required for effective eradication of large tumors

50. Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies

Catalog

Books, media, physical & digital resources